Zacks Research Issues Negative Forecast for CORT Earnings

Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) - Zacks Research reduced their Q1 2025 EPS estimates for shares of Corcept Therapeutics in a research note issued on Wednesday, December 18th. Zacks Research analyst K. Das now expects that the biotechnology company will earn $0.27 per share for the quarter, down from their prior estimate of $0.29. The consensus estimate for Corcept Therapeutics' current full-year earnings is $1.35 per share. Zacks Research also issued estimates for Corcept Therapeutics' Q2 2025 earnings at $0.34 EPS, Q3 2025 earnings at $0.42 EPS, Q4 2025 earnings at $0.53 EPS, Q2 2026 earnings at $0.55 EPS, Q3 2026 earnings at $0.71 EPS and FY2026 earnings at $2.41 EPS.

A number of other research firms have also recently issued reports on CORT. StockNews.com cut Corcept Therapeutics from a "strong-buy" rating to a "buy" rating in a report on Monday, November 25th. Truist Financial upped their price objective on Corcept Therapeutics from $65.00 to $76.00 and gave the company a "buy" rating in a report on Monday, September 30th. Piper Sandler lifted their price target on shares of Corcept Therapeutics from $38.00 to $67.00 and gave the stock an "overweight" rating in a research report on Wednesday, September 18th. HC Wainwright reiterated a "buy" rating and set a $80.00 price objective on shares of Corcept Therapeutics in a report on Thursday, October 31st. Finally, Sandler O'Neill reaffirmed a "buy" rating on shares of Corcept Therapeutics in a research note on Friday, October 18th. Six analysts have rated the stock with a buy rating, According to data from MarketBeat, Corcept Therapeutics presently has a consensus rating of "Buy" and an average target price of $65.25.

Corcept Therapeutics Stock Performance

Shares of NASDAQ CORT traded up $0.25 during trading hours on Friday, hitting $51.40. 2,456,297 shares of the stock were exchanged, compared to its average volume of 1,158,141. The company's 50 day moving average is $53.83 and its 200 day moving average is $41.92. The firm has a market capitalization of $5.39 billion, a P/E ratio of 40.79 and a beta of 0.51. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.70 and a quick ratio of 3.64. Corcept Therapeutics has a one year low of $20.84 and a one year high of $62.22.

Corcept Therapeutics (NASDAQ:CORT - Get Free Report) last announced its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported $0.41 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.27 by $0.14. The business had revenue of $182.55 million during the quarter, compared to analyst estimates of $171.97 million. Corcept Therapeutics had a return on equity of 24.54% and a net margin of 22.35%. Corcept Therapeutics's quarterly revenue was up 47.7% compared to the same quarter last year. During the same period last year, the company earned $0.28 earnings per share.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. State Street Corp raised its holdings in Corcept Therapeutics by 0.6% during the third quarter. State Street Corp now owns 3,519,263 shares of the biotechnology company's stock worth $162,871,000 after buying an additional 19,893 shares during the last quarter. Dimensional Fund Advisors LP grew its position in shares of Corcept Therapeutics by 4.2% during the 2nd quarter. Dimensional Fund Advisors LP now owns 2,676,335 shares of the biotechnology company's stock valued at $86,952,000 after acquiring an additional 108,658 shares during the period. Geode Capital Management LLC increased its position in Corcept Therapeutics by 4.4% in the third quarter. Geode Capital Management LLC now owns 2,378,758 shares of the biotechnology company's stock worth $110,108,000 after buying an additional 99,470 shares during the last quarter. FMR LLC increased its holdings in Corcept Therapeutics by 24.6% in the 3rd quarter. FMR LLC now owns 1,363,922 shares of the biotechnology company's stock worth $63,122,000 after acquiring an additional 269,074 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. increased its stake in shares of Corcept Therapeutics by 40.5% in the third quarter. Jacobs Levy Equity Management Inc. now owns 1,223,781 shares of the biotechnology company's stock worth $56,637,000 after purchasing an additional 352,947 shares in the last quarter. 93.61% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Corcept Therapeutics

In related news, insider Joseph Douglas Lyon sold 1,411 shares of the business's stock in a transaction on Friday, November 22nd. The shares were sold at an average price of $56.72, for a total value of $80,031.92. Following the sale, the insider now owns 8,494 shares of the company's stock, valued at $481,779.68. The trade was a 14.25 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Daniel N. Swisher, Jr. sold 2,200 shares of the firm's stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $59.88, for a total value of $131,736.00. The disclosure for this sale can be found here. Insiders have sold 26,811 shares of company stock valued at $1,341,360 over the last three months. 20.50% of the stock is owned by insiders.

Corcept Therapeutics Company Profile

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.